154 related articles for article (PubMed ID: 38294335)
1. Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA.
Ailawadhi S; Ravelo A; Ng CD; Shah B; Lamarre N; Wang R; Eakle K; Biondo JM
J Comp Eff Res; 2024 Feb; 13(2):e230119. PubMed ID: 38294335
[No Abstract] [Full Text] [Related]
2. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.
Kumar V; Ailawadhi S; Bojanini L; Mehta A; Biswas S; Sher T; Roy V; Vishnu P; Marin-Acevedo J; Alegria VR; Paulus A; Aulakh S; Iqbal M; Manochakian R; Tan W; Chanan-Khan A; Ailawadhi M
Blood Cancer J; 2019 Sep; 9(10):75. PubMed ID: 31570695
[TBL] [Abstract][Full Text] [Related]
3. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study.
Duchesneau ED; McNeill AM; Schary W; Pate V; Lund JL
J Geriatr Oncol; 2023 Nov; 14(8):101602. PubMed ID: 37696241
[TBL] [Abstract][Full Text] [Related]
5. Second cancers in patients with chronic lymphocytic leukemia.
Travis LB; Curtis RE; Hankey BF; Fraumeni JF
J Natl Cancer Inst; 1992 Sep; 84(18):1422-7. PubMed ID: 1512794
[TBL] [Abstract][Full Text] [Related]
6. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
7. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.
Mishra R; Dima D; Kumar SA; Mian A; Taneja A; Karna R; Caimi PF; Hill BT; Dean R; Jagadeesh D
Hematol Oncol; 2023 Dec; 41(5):884-893. PubMed ID: 37309225
[TBL] [Abstract][Full Text] [Related]
8. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.
van der Straten L; Levin MD; Dinnessen MAW; Visser O; Posthuma EFM; Doorduijn JK; Langerak AW; Kater AP; Dinmohamed AG
Blood Cancer J; 2023 Jan; 13(1):15. PubMed ID: 36635262
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.
Falchi L; Vitale C; Keating MJ; Lerner S; Wang X; Elhor Gbito KY; Strom S; Wierda WG; Ferrajoli A
Ann Oncol; 2016 Jun; 27(6):1100-1106. PubMed ID: 26912560
[TBL] [Abstract][Full Text] [Related]
12. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
13. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
[TBL] [Abstract][Full Text] [Related]
14. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Tsimberidou AM; Wen S; McLaughlin P; O'Brien S; Wierda WG; Lerner S; Strom S; Freireich EJ; Medeiros LJ; Kantarjian HM; Keating MJ
J Clin Oncol; 2009 Feb; 27(6):904-10. PubMed ID: 19114699
[TBL] [Abstract][Full Text] [Related]
15. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M
JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850
[TBL] [Abstract][Full Text] [Related]
16. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
17. Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA; Huang Y; Fisher JL; Ruppert AS; Owen DH; Bertino EM; Rogers KA; Bhat SA; Grever MR; Jaglowski SM; Maddocks KJ; Byrd JC; Woyach JA
Leukemia; 2020 Dec; 34(12):3197-3205. PubMed ID: 32704159
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia and secondary hematological malignancies: A nation-wide cancer registry study.
Lenartova A; Johannesen TB; Tjønnfjord GE
Eur J Haematol; 2020 Jun; 104(6):546-553. PubMed ID: 32058605
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.
Yang J; Wu F; An H; Gan H
Int J Colorectal Dis; 2023 Mar; 38(1):88. PubMed ID: 36995483
[TBL] [Abstract][Full Text] [Related]
20. Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis.
Jia H; Li Q; Yuan J; Sun X; Wu Z
Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31943509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
